Canada Pension Plan Investment Board Buys 39,070 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Canada Pension Plan Investment Board grew its position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 5.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 805,615 shares of the biopharmaceutical company's stock after purchasing an additional 39,070 shares during the quarter. Canada Pension Plan Investment Board owned 0.14% of Royalty Pharma worth $20,551,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of RPRX. Barclays PLC boosted its position in shares of Royalty Pharma by 16.3% during the 3rd quarter. Barclays PLC now owns 308,887 shares of the biopharmaceutical company's stock valued at $8,737,000 after purchasing an additional 43,339 shares in the last quarter. Sanctuary Advisors LLC lifted its position in shares of Royalty Pharma by 78.9% in the third quarter. Sanctuary Advisors LLC now owns 41,466 shares of the biopharmaceutical company's stock worth $1,096,000 after purchasing an additional 18,288 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new position in shares of Royalty Pharma during the 3rd quarter valued at $61,000. Franklin Resources Inc. raised its position in Royalty Pharma by 5.0% during the third quarter. Franklin Resources Inc. now owns 1,460,515 shares of the biopharmaceutical company's stock valued at $40,705,000 after acquiring an additional 70,130 shares in the last quarter. Finally, GAMMA Investing LLC raised its holdings in Royalty Pharma by 31.4% during the fourth quarter. GAMMA Investing LLC now owns 2,471 shares of the biopharmaceutical company's stock valued at $63,000 after buying an additional 590 shares in the last quarter. Institutional investors and hedge funds own 54.35% of the company's stock.

Royalty Pharma Price Performance

Royalty Pharma stock traded up $0.13 during trading hours on Friday, hitting $32.16. 1,035,112 shares of the stock were exchanged, compared to its average volume of 3,244,572. The business's 50-day moving average is $32.54 and its two-hundred day moving average is $29.39. Royalty Pharma plc has a 12 month low of $24.05 and a 12 month high of $34.20. The stock has a market capitalization of $18.54 billion, a P/E ratio of 22.19, a P/E/G ratio of 2.31 and a beta of 0.50. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. Equities research analysts expect that Royalty Pharma plc will post 4.49 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be paid a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a dividend yield of 2.74%. The ex-dividend date is Friday, May 16th. Royalty Pharma's dividend payout ratio (DPR) is presently 60.69%.

Analyst Upgrades and Downgrades

Separately, Citigroup reiterated a "buy" rating on shares of Royalty Pharma in a report on Friday, March 28th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $42.50.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.